Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
German biosimilars company Formycon and Jordan-based MS Pharma have announced that FYB201, a biosimilar to Lucentis (ranibizumab), has received marketing author 11 March 2024
Medicines for Europe, a trade group for the European generics industry, has welcomed the position adopted today by the European Parliament regarding SPC regulat 28 February 2024
The US Department of Veterans Affairs (VA) has exclusively selected Organon's Hadlima in replacement of Humira (adalimumab) for the VA National Formulary. 21 February 2024